Antikoagulantna terapija i reverzija antikoagulantnog učinka

Reversal of antithrombotic agents. (otvara se novi prozor)

Bauer KA.

Izvor‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Indeks‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (otvara se novi prozor)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (otvara se novi prozor)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Izvor‎: J Thromb Haemost 2015;13(10):1790-8.

Indeks‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (otvara se novi prozor)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (otvara se novi prozor)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Izvor‎: N Engl J Med 2019;380(14):1326-35.

Indeks‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (otvara se novi prozor)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (otvara se novi prozor)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Izvor‎: N Engl J Med 2016;375(12):1131-41.

Indeks‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (otvara se novi prozor)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (otvara se novi prozor)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Izvor‎: Circulation 2011;124(14):1573-9.

Indeks‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (otvara se novi prozor)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (otvara se novi prozor)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Izvor‎: Lancet 2015;385(9982):2077-87.

Indeks‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (otvara se novi prozor)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (otvara se novi prozor)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Izvor‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Indeks‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (otvara se novi prozor)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (otvara se novi prozor)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Izvor‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Indeks‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (otvara se novi prozor)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (otvara se novi prozor)

Levi M, Eerenberg E, Kamphuisen PW.

Izvor‎: J Thromb Haemost 2011;9(9):1705-12.

Indeks‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (otvara se novi prozor)

Emergency reversal of warfarin anticoagulation. (otvara se novi prozor)

Lin Y, Callum J.

Izvor‎: CMAJ 2010;182(18):2004.

Indeks‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (otvara se novi prozor)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (otvara se novi prozor)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Izvor‎: Thromb Haemost 2012;108(2):217-24.

Indeks‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (otvara se novi prozor)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (otvara se novi prozor)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Izvor‎: J Thromb Haemost 2008;6(4):622-31.

Indeks‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (otvara se novi prozor)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (otvara se novi prozor)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Izvor‎: Blood Adv 2019;3(2):158-67.

Indeks‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (otvara se novi prozor)

Idarucizumab for dabigatran reversal. (otvara se novi prozor)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Izvor‎: N Engl J Med 2015;373(6):511-20.

Indeks‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (otvara se novi prozor)

Idarucizumab for dabigatran reversal - full cohort analysis. (otvara se novi prozor)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Izvor‎: N Engl J Med 2017;377(5):431-41.

Indeks‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (otvara se novi prozor)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (otvara se novi prozor)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Izvor‎: Blood 2003;102(13):4594-9.

Indeks‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (otvara se novi prozor)

Role of agents for reversing the effects of target-specific oral anticoagulants. (otvara se novi prozor)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Izvor‎: Am J Health Syst Pharm 2017;74(2):54-61.

Indeks‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (otvara se novi prozor)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (otvara se novi prozor)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Izvor‎: Anesth Analg 2011;113(4):703-10.

Indeks‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (otvara se novi prozor)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (otvara se novi prozor)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Izvor‎: J Am Coll Cardiol 2017;70(24):3042-67.

Indeks‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (otvara se novi prozor)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (otvara se novi prozor)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Izvor‎: World Neurosurg 2014;81(1):110-5.

Indeks‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (otvara se novi prozor)

Reversal of warfarin-induced hemorrhage in the emergency department. (otvara se novi prozor)

Zareh M, Davis A, Henderson S.

Izvor‎: West J Emerg Med 2011;12(4):386-92.

Indeks‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (otvara se novi prozor)

INTENZIVNA I POJAČANA SKRB

Antikoagulantna terapija i reverzija antikoagulantnog učinka

hrvatski

Antikoagulantna terapija i reverzija antikoagulantnog učinka

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Antikoagulantna terapija i reverzija antikoagulantnog učinka

Reversal of antithrombotic agents. (otvara se novi prozor)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (otvara se novi prozor)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (otvara se novi prozor)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (otvara se novi prozor)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (otvara se novi prozor)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (otvara se novi prozor)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (otvara se novi prozor)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (otvara se novi prozor)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (otvara se novi prozor)

Emergency reversal of warfarin anticoagulation. (otvara se novi prozor)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (otvara se novi prozor)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (otvara se novi prozor)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (otvara se novi prozor)

Idarucizumab for dabigatran reversal. (otvara se novi prozor)

Idarucizumab for dabigatran reversal - full cohort analysis. (otvara se novi prozor)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (otvara se novi prozor)

Role of agents for reversing the effects of target-specific oral anticoagulants. (otvara se novi prozor)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (otvara se novi prozor)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (otvara se novi prozor)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (otvara se novi prozor)

Reversal of warfarin-induced hemorrhage in the emergency department. (otvara se novi prozor)

Kontaktirajte predstavnike Odbora za kontaktiranje s bolnicama u svojoj zemlji

Preuzmite medicinske informacije

Filmovi

Antikoagulantna terapija i reverzija antikoagulantnog učinka

Izaberi svoj jezik

Podijeli